Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

NEXT STORY
Allarity Therapeutics Publishes Interim Report for the Period January – March 2021
PREV STORY
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)

author_avatar
NASDAQ Market News

Francis Collins Awarded 2020 Templeton Prize

author_avatar
NASDAQ Market News

Medtronic Receives FDA Approval of New Pediatric Indication for the MiniMed(TM) 670G Hybrid Closed Loop System in Children Ages 7-13

DUBLIN- June 21, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, ...

author_avatar
NASDAQ Market News